---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009147"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:02:39.067717+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Takeda notifies Ovid of soticlestat Phase 3 delays; primary completion March 2024

## Summary
- Takeda notified Ovid that two pivotal Phase 3 soticlestat trials (Dravet & Lennox-Gastaut) are likely delayed due to Ukraine/Russia and China COVID lockdowns.
- Primary completion date now estimated March 2024; regulatory filings expected in Takeda's fiscal 2024.
- Takeda stated studies remain highest-priority late-stage programs; actively recruiting with multiple approaches to minimize delays.
- Ovid retains significant financial interest in soticlestat's development and potential commercialization.

## SEC filing metadata
- accession: 0000950170-22-009147
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000095017022009147/0000950170-22-009147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000095017022009147/ovid-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009147
- JSON: https://secwatch.observer/filing/0000950170-22-009147.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.